PicoCELA Inc. (NASDAQ:PCLA) Short Interest Down 46.7% in January

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totaling 1,932,063 shares, a drop of 46.7% from the December 31st total of 3,625,291 shares. Based on an average daily volume of 4,234,824 shares, the days-to-cover ratio is currently 0.5 days. Currently, 212.3% of the company’s stock are sold short. Currently, 212.3% of the company’s stock are sold short. Based on an average daily volume of 4,234,824 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Investors Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd bought a new position in PicoCELA Inc. (NASDAQ:PCLA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned approximately 0.16% of PicoCELA as of its most recent SEC filing.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a report on Friday, January 9th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

PicoCELA Price Performance

NASDAQ PCLA traded up $0.56 during trading hours on Friday, hitting $6.33. The company had a trading volume of 45,830 shares, compared to its average volume of 103,227. PicoCELA has a fifty-two week low of $3.46 and a fifty-two week high of $294.00. The business has a fifty day simple moving average of $7.59 and a 200-day simple moving average of $11.67.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.